Progress on Phage Display Technology: Tailoring Antibodies for Cancer Immunotherapy
Authors:
- Renato Kaylan Alves FrançaRFRenato Kaylan Alves França
- Igor Cabral StudartISIgor Cabral Studart
- Marcus Rafael Lobo BezerraMBMarcus Rafael Lobo Bezerra
- Larissa Queiroz PontesLPLarissa Queiroz Pontes
- Antonio Marcos Aires BarbosaABAntonio Marcos Aires Barbosa
- Marcelo Macedo BrigidoMBMarcelo Macedo Brigido
- Gilvan Pessoa FurtadoGFGilvan Pessoa Furtado
- Andréa Queiroz MaranhãoAndréa Queiroz Maranhão
Open Access
Abstract
The search for innovative anti-cancer drugs remains a challenge. Over the past three decades, antibodies have emerged as an essential asset in successful cancer therapy. The major obstacle in developing anti-cancer antibodies is the need for non-immunogenic antibodies against human antigens. This unique requirement highlights a disadvantage to using traditional hybridoma technology and thus demands alternative approaches, such as humanizing murine monoclonal antibodies. To overcome these hurdles, human monoclonal antibodies can be obtained directly from Phage Display libraries, a groundbreaking tool for antibody selection. These libraries consist of genetically engineered viruses, or phages, which can exhibit antibody fragments, such as scFv or Fab on their capsid. This innovation allows the in vitro selection of novel molecules directed towards cancer antigens. As foreseen when Phage Display was first described, nowadays, several Phage Display-derived antibodies have entered clinical settings or are undergoing clinical evaluation. This comprehensive review unveils the remarkable progress in this field and the possibilities of using clever strategies for phage selection and tailoring the refinement of antibodies aimed at increasingly specific targets. Moreover, the use of selected antibodies in cutting-edge formats is discussed, such as CAR (chimeric antigen receptor) in CAR T-cell therapy or ADC (antibody drug conjugate), amplifying the spectrum of potential therapeutic avenues.Keywords
Funding Information
- FAP-DF (00193-00000229/2021-21, 001, 442569/2020-3, 00193-00000229/2021-21)
- CAPES (00193-00000229/2021-21, 001, 442569/2020-3, 00193-00000229/2021-21)
- CNPq-DCIT (00193-00000229/2021-21, 001, 442569/2020-3, 00193-00000229/2021-21)
- FAP-DF (00193-00000229/2021-21, 001, 442569/2020-3, 00193-00000229/2021-21)
This publication has 183 references indexed in Scilit:
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- An improved phage-display panning method to produce an HM-1 killer toxin anti-idiotypic antibodyBMC Biotechnology, 2009
- New perspective for phage display as an efficient and versatile technology of functional proteomicsApplied Microbiology and Biotechnology, 2009
- Chromato-panning: an efficient new mode of identifying suitable ligands from phage display librariesBMC Biotechnology, 2009
- Isolation of Osteosarcoma‐Associated Human Antibodies from a Combinatorial Fab Phage Display LibraryBioMed Research International, 2009
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 2008
- Phage antibodies: filamentous phage displaying antibody variable domainsNature, 1990
- Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coliNature, 1989